Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/27/2024 | $20.00 | Strong Buy | Raymond James |
| 5/10/2023 | $8.00 → $20.00 | Buy | Maxim Group |
| 10/4/2021 | $25.00 | Buy | Alliance Global Partners |
| 6/23/2021 | $23.00 | Outperform | Oppenheimer |
SC 13G - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
SC 13G - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
Raymond James initiated coverage of Achieve Life Sciences with a rating of Strong Buy and set a new price target of $20.00
Maxim Group reiterated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $20.00 from $8.00 previously
Alliance Global Partners initiated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $25.00
SCHEDULE 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
SCHEDULE 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)
8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)
SEATTLE and VANCOUVER, British Columbia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced it will report its third quarter 2024 financial results and provide a corporate update on the cytisinicline development program on Thursday, November 7, 2024, at 4:30 PM EST. To access the webcast, please use the following link: 3Q24 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 1 201-689-7817 (International) and referencing
SEATTLE and VANCOUVER, British Columbia, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, announced that Dr. Cindy Jacobs, Achieve's President and Chief Medical Officer, presented at the U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH) Joint Public Meeting on "Advancing Smoking Cessation: FDA and NIH Priorities" held on October 21, 2024. The public meeting was initiated by Robert Califf, M.D., who currently serves as the 25th Commissioner of the FDA. The meeting included other
SEATTLE and VANCOUVER, British Columbia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, is pleased to announce the promotion of Ms. Jaime Xinos to Chief Commercial Officer, effective immediately. Ms. Xinos has been with Achieve Life Sciences since 2017, serving as Executive Vice President of Commercial. In her expanded role, she will oversee all commercial operations and lead the company's strategic preparations for the anticipated U.S. launch of cytisinicline. This includes driving readiness across key stake
SEATTLE and VANCOUVER, British Columbia, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced it will report its third quarter 2024 financial results and provide a corporate update on the cytisinicline development program on Thursday, November 7, 2024, at 4:30 PM EST. To access the webcast, please use the following link: 3Q24 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 1 201-689-7817 (International) and referencing
SEATTLE and VANCOUVER, British Columbia, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced its financial results for the second quarter of 2024 and provided an update on its cytisinicline development program. Recent Highlights The FDA granted Breakthrough Therapy designation for cytisinicline treatment of nicotine e-cigarette, or vaping, cessationCompleted refinancing and extended the maturity date of outstanding term loans with Silicon Valley Bank (SVB)Joined the U.S. Russell 3000® and Rus
SEATTLE and VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its second quarter 2024 financial results and provide an update on the cytisinicline development program on Tuesday, August 13, 2024, at 4:30 PM EDT. To access the webcast, please use the following link: 2Q24 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and referencing conference ID 137473
3 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa
FORT WORTH, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Thomas B. King to its Board of Directors. "I am pleased to welcome Thomas King to our Board of Directors," said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Pharmaceuticals. "Tom is an exceptionally accomplished executive who has held leadership positions at life sciences companies over the last three decades. In addition, his extensive board experience will p
SEATTLE and VANCOUVER, British Columbia, March 14, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, is pleased to announce the appointment of Dr. Vaughn Himes to the company's Board of Directors, effective immediately. "We are pleased to welcome Dr. Himes to the Achieve board," commented Rick Stewart, Executive Chairman of the Board of Directors. "As we continue to advance the cytisinicline clinical development program towards commercialization, Dr. Himes' deep background and expertise will offer invaluable
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)
4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)